- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06513156
Kontinuum af pleje hos indlagte patienter med opioidbrugsforstyrrelse og smitsomme komplikationer fra stofbrug (CHOICE-STAR)
Kontinuum af pleje hos hospitalsindlagte patienter med opioidbrugsforstyrrelse og infektiøse komplikationer af stofbrug - NavSTAR, behandling som sædvanlig, afhængighed/ID integreret klinik for at forhindre infektionsrelateret genindlæggelse
This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
This is a phase III two arm randomized controlled trial to determine the impact and Integrated infectious diseases (ID) and Substance Use Disorder outpatient clinic (IC) compared to treatment as usual on infection related rehospitalization in individuals hospitalized with infections due to injecting opioids or Stimulants, in the 6 month time period after discharge. This study includes both cost effectiveness and implementation outcomes.
(1) IC will provide facilitated linkage to a clinic providing medical treatment aimed at treating substance use disorder (SUD), resolving the index infection, treating existing ID complications of OUD (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and medication for OUD (MOUD) treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and MOUD providers.
The study will recruit patients during hospitalization for an infection due to injecting opioids or stimulants at four hospital systems (five hospitals) and randomly assign approximately 304 inpatients in 1:1 ratio to IC vs TAU.
Participants will be followed for 12 months.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Rachel Silk
- Telefonnummer: 301-326-7652
- E-mail: rsilk@ihv.umaryland.edu
Studiesteder
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20052
- Rekruttering
- George Washington University
-
Underforsker:
- Irene Kuo, MD
-
Kontakt:
- Jill Catalanotti, MD
- E-mail: jcatalanotti@mfa.gwu.edu
-
Ledende efterforsker:
- Jill Catalanotti, MD
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University
-
Ledende efterforsker:
- Joseph Carpenter, MD
-
Kontakt:
- Joseph Carpenter, MD
- E-mail: joseph.edward.carpenter@emory.edu
-
Underforsker:
- Alina Steck, MD
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- Rekruttering
- University of Maryland Baltimore
-
Underforsker:
- Edward Traver, MD
-
Ledende efterforsker:
- Elana Rosenthal, MD
-
Underforsker:
- Sarah Kattakuzhy, MD
-
Kontakt:
- Rachel Silk
- Telefonnummer: 3013267652
- E-mail: rsilk@ihv.umaryland.edu
-
-
West Virginia
-
Morgantown, West Virginia, Forenede Stater, 26506
- Rekruttering
- West Virginia University
-
Kontakt:
- Rebecca Reece, MD
- E-mail: rreece@hsc.wvu.edu
-
Ledende efterforsker:
- Rebecca Reece, MD
-
Underforsker:
- Clinton Cooper, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years
- Admitted to study hospital (defined as hospitalized with a primary team that is not Emergency Medicine)
- Injection opioid or stimulant use in past 90 days - per patient self-report
- Active suspected or confirmed qualifying infection (see list) at time of admission.
Qualifying infections:
- Non-vertebral osteomyelitis
- Vertebral osteomyelitis or discitis
- Epidural, subdural, or extradural abscess
- Intracranial or intraspinal abscess
- Native joint septic arthritis
- Prosthetic joint septic arthritis
- Blood stream infection (bacterial or fungal)
- Native valve Endocarditis
- Prosthetic valve endocarditis
- Cardiac Implantable electronic device infection
- Infectious pseudoaneurysm and aneurysm
- Infected vascular graft
- Septic venous thrombosis
- Skin and Soft tissue infection (cellulitis, skin abscess, necrotizing fasciitis)
- Infected skin ulcer
- Orthopedic hardware infection
- Muscle abscess/myositis
- Central nervous system infection (bacterial or fungal)
- Bacterial or fungal ophthalmologic infection
- Other abscess
- Pulmonary septic emboli
- Other acute bacterial or fungal infection deemed appropriate by site study team
Exclusion Criteria:
-
1. Infection due to a cause other than injection drug use, per determination of a site PI.
2. Inability to provide consent due to circumstance (e.g., sedated, intubated), language, or cognitive impairment.
3. Unwilling to provide informed consent 4. Unable to receive potential interventions due to geography 5. On comfort measures or planned for discharge to hospice care 6. Incarcerated at the time of hospitalization 7. Other criteria at the discretion of the site investigator
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: Treatment As Usual
Will receive treatment for infection and opioid or stimulant use disorder per the usual care at each hospital |
|
|
Eksperimentel: Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)
The Integrated ID/SUD Clinic will provide facilitated linkage to a clinic providing medical treatment aimed at treating SUD, resolving the sentinel infection, treating existing ID complications of OUD/stimulants (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and MOUD treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and SUD providers. The dual goals of the IC intervention are to 1) to facilitate accessibility to ID and OUD care and 2) to ensure care coordination between outpatient ID and SUD providers. |
Integrated medication for opioid/stimulant use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Infection Rehospitalization
Tidsramme: 6 months after discharge for index hospitalization
|
New hospitalization due to infection following discharge for index hospitalization |
6 months after discharge for index hospitalization
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to first infection related readmission
Tidsramme: 12 months after discharge for index hospitalization
|
Time to first infection related readmission |
12 months after discharge for index hospitalization
|
|
Reason for infection related readmission
Tidsramme: 12 months after discharge for index hospitalization
|
Reason for infection related readmission (persistent index infection, new IDU associated infection, other infection) |
12 months after discharge for index hospitalization
|
|
Hospital services utilization
Tidsramme: 12 months after discharge for index hospitalization
|
ED visits (Binary, count, time to first ED visit, cause) and Readmission, all cause (binary, count, time to first readmission, cause) |
12 months after discharge for index hospitalization
|
|
Mortality
Tidsramme: 12 months after discharge for index hospitalization
|
Death (Binary, time to death, cause of death) |
12 months after discharge for index hospitalization
|
|
Index infection
Tidsramme: 3 months after discharge for index hospitalization
|
Completion of antibiotics (binary, reason for incomplete antibiotics); Resolution of index infection (binary) Skilled Nursing Facility (SNF) Admitted to SNF (binary) Discharge type from SNF (planned, PDD, dead, transfer) |
3 months after discharge for index hospitalization
|
|
Other Infections
Tidsramme: 12 months after discharge for index hospitalization
|
HCV Active HCV (binary) Clinical evaluation (binary) DAA prescribed (binary) DAA initiated (binary) SVR achieved (binary) HIV Diagnosis status (binary) HIV VL undetectable (binary) ART Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) PrEP Eligible (CDC Criteria, binary, indication) Offered by healthcare provider (binary) Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) |
12 months after discharge for index hospitalization
|
|
Skin and soft tissue wounds
Tidsramme: 12 months after discharge for index hospitalization
|
Present (binary) Number (count) Per wound Size Location on body Duration (continuous) |
12 months after discharge for index hospitalization
|
|
New infections not requiring hospitalization
Tidsramme: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Outpatient linkage and retention
Tidsramme: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Medication for Opioid Use (MOUD)
Tidsramme: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Medication for stimulant use (MStUD)
Tidsramme: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Substance Use-Opioid
Tidsramme: 12 months after discharge for index hospitalization
|
Ongoing opioid (binary, mode)
|
12 months after discharge for index hospitalization
|
|
Substance Use - Stimulant
Tidsramme: 12 months after discharge for index hospitalization
|
Ongoing stimulant use (binary, mode)
|
12 months after discharge for index hospitalization
|
|
Cost Effectiveness
Tidsramme: 12 months after discharge for index hospitalization
|
• ICER for quality adjusted life years (QALYs); opioid-free years (OfYs); and infection-free years (IfYs) gained |
12 months after discharge for index hospitalization
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Elana Rosenthal, MD, University of Maryland, Baltimore
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HP-00111318
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .